Cargando…
Inhibition of FASN suppresses the malignant biological behavior of non-small cell lung cancer cells via deregulating glucose metabolism and AKT/ERK pathway
BACKGROUND: Fatty acid synthase (FASN) is overexpressed in most human carcinomas, including non-small cell lung cancer (NSCLC), and contributes to poor prognosis. An increasing number of studies have highlighted the potential function of FASN as both a biomarker and therapeutic target for cancers. H...
Autores principales: | Chang, Ligong, Fang, Surong, Chen, Yubao, Yang, Zhenhua, Yuan, Yuan, Zhang, Jing, Ye, Liang, Gu, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533754/ https://www.ncbi.nlm.nih.gov/pubmed/31122252 http://dx.doi.org/10.1186/s12944-019-1058-8 |
Ejemplares similares
-
Deregulation of tumor suppressive ASXL1−PTEN/AKT axis in myeloid malignancies
por: Cao, Lei, et al.
Publicado: (2020) -
Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt
por: Xiong, Wenfang, et al.
Publicado: (2021) -
Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations
por: Stamatakos, Serena, et al.
Publicado: (2021) -
FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles
por: Ricklefs, Franz L., et al.
Publicado: (2020) -
Deregulation of Interferon Signaling in Malignant Cells
por: Katsoulidis, Efstratios, et al.
Publicado: (2010)